Radius Health Inc (RDUS) Stock: What Does the Chart Say?

Thursday, September 24, 2020 1:40 PM | InvestorsObserver Analysts

Overall market sentiment has been down on Radius Health Inc (RDUS) stock lately. RDUS receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bearish
Radius Health Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RDUS!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With RDUS Stock Today?

Radius Health Inc (RDUS) stock is trading at $11.18 as of 1:36 PM on Thursday, Sep 24, a loss of -$0.12, or -1.06% from the previous closing price of $11.30. The stock has traded between $10.72 and $11.29 so far today. Volume today is 415,026 compared to average volume of 534,114.

To screen for more stocks like Radius Health Inc click here.

More About Radius Health Inc

Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140.

Click Here to get the full Stock Score Report on Radius Health Inc (RDUS) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Sector Update: Biotech Stocks Help Drag Health Care Sector Lower

Sector Update: Health Care

How Will the Market React to Gamida Cell Ltd (GMDA) Stock Getting a Bullish Rating

Is OrganiGram Holdings Inc (OGI) Stock About to Get Hot Monday?

Related Companies